Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.94
TKPYY's Cash to Debt is ranked higher than
67% of the 921 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. TKPYY: 0.94 )
TKPYY' s 10-Year Cash to Debt Range
Min: 0.7   Max: No Debt
Current: 0.94

Equity to Asset 0.55
TKPYY's Equity to Asset is ranked higher than
65% of the 842 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. TKPYY: 0.55 )
TKPYY' s 10-Year Equity to Asset Range
Min: 0.55   Max: 0.78
Current: 0.55

0.55
0.78
Interest Coverage 4.53
TKPYY's Interest Coverage is ranked higher than
51% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 176.76 vs. TKPYY: 4.53 )
TKPYY' s 10-Year Interest Coverage Range
Min: 3.18   Max: 1856.28
Current: 4.53

3.18
1856.28
F-Score: 6
Z-Score: 2.68
M-Score: -3.52
WACC vs ROIC
6.54%
2.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 9.26
TKPYY's Operating margin (%) is ranked higher than
75% of the 870 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.37 vs. TKPYY: 9.26 )
TKPYY' s 10-Year Operating margin (%) Range
Min: 4.17   Max: 35.13
Current: 9.26

4.17
35.13
Net-margin (%) 3.16
TKPYY's Net-margin (%) is ranked higher than
67% of the 870 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. TKPYY: 3.16 )
TKPYY' s 10-Year Net-margin (%) Range
Min: 6.48   Max: 26.26
Current: 3.16

6.48
26.26
ROE (%) 2.19
TKPYY's ROE (%) is ranked higher than
66% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. TKPYY: 2.19 )
TKPYY' s 10-Year ROE (%) Range
Min: 4.49   Max: 24.22
Current: 2.19

4.49
24.22
ROA (%) 1.22
TKPYY's ROA (%) is ranked higher than
66% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. TKPYY: 1.22 )
TKPYY' s 10-Year ROA (%) Range
Min: 2.54   Max: 16.8
Current: 1.22

2.54
16.8
ROC (Joel Greenblatt) (%) 21.41
TKPYY's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.08 vs. TKPYY: 21.41 )
TKPYY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 9.38   Max: 154.35
Current: 21.41

9.38
154.35
Revenue Growth (3Y)(%) 6.00
TKPYY's Revenue Growth (3Y)(%) is ranked higher than
75% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.30 vs. TKPYY: 6.00 )
TKPYY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0.2   Max: 11.6
Current: 6

0.2
11.6
EBITDA Growth (3Y)(%) -5.50
TKPYY's EBITDA Growth (3Y)(%) is ranked higher than
66% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. TKPYY: -5.50 )
TKPYY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -9   Max: 24.8
Current: -5.5

-9
24.8
EPS Growth (3Y)(%) -24.50
TKPYY's EPS Growth (3Y)(%) is ranked higher than
59% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. TKPYY: -24.50 )
TKPYY' s 10-Year EPS Growth (3Y)(%) Range
Min: -24.5   Max: 31.4
Current: -24.5

-24.5
31.4
» TKPYY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TKPYY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 90.60
TKPYY's P/E(ttm) is ranked higher than
67% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.40 vs. TKPYY: 90.60 )
TKPYY' s 10-Year P/E(ttm) Range
Min: 7.81   Max: 98.14
Current: 90.6

7.81
98.14
Forward P/E 33.33
TKPYY's Forward P/E is ranked higher than
76% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.57 vs. TKPYY: 33.33 )
N/A
PE(NRI) 93.70
TKPYY's PE(NRI) is ranked higher than
70% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.00 vs. TKPYY: 93.70 )
TKPYY' s 10-Year PE(NRI) Range
Min: 7.81   Max: 98.14
Current: 93.7

7.81
98.14
P/B 2.00
TKPYY's P/B is ranked higher than
83% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. TKPYY: 2.00 )
TKPYY' s 10-Year P/B Range
Min: 1.19   Max: 2.15
Current: 2

1.19
2.15
P/S 2.76
TKPYY's P/S is ranked higher than
71% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.26 vs. TKPYY: 2.76 )
TKPYY' s 10-Year P/S Range
Min: 1.67   Max: 12.29
Current: 2.76

1.67
12.29
PFCF 116.70
TKPYY's PFCF is ranked higher than
75% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 639.25 vs. TKPYY: 116.70 )
TKPYY' s 10-Year PFCF Range
Min: 6.38   Max: 126.23
Current: 116.7

6.38
126.23
POCF 31.33
TKPYY's POCF is ranked higher than
78% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 37.05 vs. TKPYY: 31.33 )
TKPYY' s 10-Year POCF Range
Min: 4.99   Max: 66.83
Current: 31.33

4.99
66.83
EV-to-EBIT 31.75
TKPYY's EV-to-EBIT is ranked higher than
78% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.20 vs. TKPYY: 31.75 )
TKPYY' s 10-Year EV-to-EBIT Range
Min: 4.3   Max: 67.2
Current: 31.75

4.3
67.2
Shiller P/E 26.20
TKPYY's Shiller P/E is ranked higher than
86% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 111.29 vs. TKPYY: 26.20 )
TKPYY' s 10-Year Shiller P/E Range
Min: 10.21   Max: 27.98
Current: 26.2

10.21
27.98
Current Ratio 2.03
TKPYY's Current Ratio is ranked higher than
67% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. TKPYY: 2.03 )
TKPYY' s 10-Year Current Ratio Range
Min: 1.21   Max: 4
Current: 2.03

1.21
4
Quick Ratio 1.70
TKPYY's Quick Ratio is ranked higher than
71% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. TKPYY: 1.70 )
TKPYY' s 10-Year Quick Ratio Range
Min: 1   Max: 3.64
Current: 1.7

1
3.64
Days Inventory 192.03
TKPYY's Days Inventory is ranked higher than
63% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.81 vs. TKPYY: 192.03 )
TKPYY' s 10-Year Days Inventory Range
Min: 47.73   Max: 180.01
Current: 192.03

47.73
180.01

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.20
TKPYY's Dividend Yield is ranked higher than
91% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.42 vs. TKPYY: 3.20 )
TKPYY' s 10-Year Dividend Yield Range
Min: 1.55   Max: 5.32
Current: 3.2

1.55
5.32
Dividend Payout 2.58
TKPYY's Dividend Payout is ranked higher than
67% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. TKPYY: 2.58 )
TKPYY' s 10-Year Dividend Payout Range
Min: 0.8   Max: 6.61
Current: 2.58

0.8
6.61
Dividend growth (3y) -2.00
TKPYY's Dividend growth (3y) is ranked higher than
73% of the 364 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. TKPYY: -2.00 )
TKPYY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: -1.8
Current: -2

Yield on cost (5-Year) 2.82
TKPYY's Yield on cost (5-Year) is ranked higher than
81% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.62 vs. TKPYY: 2.82 )
TKPYY' s 10-Year Yield on cost (5-Year) Range
Min: 1.37   Max: 4.69
Current: 2.82

1.37
4.69

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 7.60
TKPYY's Price/Tangible Book is ranked higher than
57% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.88 vs. TKPYY: 7.60 )
TKPYY' s 10-Year Price/Tangible Book Range
Min: 1.8   Max: 7.51
Current: 7.6

1.8
7.51
Price/DCF (Projected) 1.20
TKPYY's Price/DCF (Projected) is ranked higher than
93% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.40 vs. TKPYY: 1.20 )
TKPYY' s 10-Year Price/DCF (Projected) Range
Min: 0.43   Max: 0.95
Current: 1.2

0.43
0.95
Price/Median PS Value 1.30
TKPYY's Price/Median PS Value is ranked higher than
75% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. TKPYY: 1.30 )
TKPYY' s 10-Year Price/Median PS Value Range
Min: 0.82   Max: 5.22
Current: 1.3

0.82
5.22
Price/Graham Number 5.50
TKPYY's Price/Graham Number is ranked higher than
68% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. TKPYY: 5.50 )
TKPYY' s 10-Year Price/Graham Number Range
Min: 0.87   Max: 4.45
Current: 5.5

0.87
4.45
Earnings Yield (Greenblatt) 3.10
TKPYY's Earnings Yield (Greenblatt) is ranked higher than
74% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. TKPYY: 3.10 )
TKPYY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.5   Max: 23.1
Current: 3.1

1.5
23.1
Forward Rate of Return (Yacktman) -10.40
TKPYY's Forward Rate of Return (Yacktman) is ranked higher than
59% of the 520 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.39 vs. TKPYY: -10.40 )
TKPYY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -17.2   Max: 17.2
Current: -10.4

-17.2
17.2

Analyst Estimate

Mar15
EPS($) 1.17
EPS without NRI($) 1.17

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:4502.Japan, TKD.Germany, 4502.Japan, 4502.Japan,
Takeda Pharmaceutical Co Ltd was founded on June 12, 1781 and was incorporated on January 29, 1925. The Company is primarily engaged in the any manufacture and sale of pharmaceuticals, food supplements, and chemical products such as polyurethane. The Company also produces food, agrochemicals, and environment-related products such as pollution detectors. It is also engaged in the research, development, and promotion of its products through its related companies in the US, Europe, and Asia.
» More Articles for TKPYY

Headlines

Articles On GuruFocus.com
Don't Quit on Teva Just Yet Feb 20 2014 
Soros´ Bet on Teva’s Transition (A Transition for Better or for Worse?) Dec 18 2013 
T. Rowe Price Japan Fund Top 5 New Buys Oct 17 2013 


More From Other Websites
Orexigen's Obesity Drug Mysimba Gains European Approval - Analyst Blog Mar 27 2015
Immunogen Reaches Licensing Deal With Takeda Mar 23 2015
Novo Nordisk's Saxenda: New Data from Phase IIIa Study - Analyst Blog Mar 09 2015
Takeda Disagrees With Orexigen Over Data Disclosure Mar 05 2015
Orexigen Soars as Interim Data on Contrave Comes to Light - Analyst Blog Mar 04 2015
Toyota Taps First Foreign Vice President Mar 04 2015
Orexigen (OREX) Misses Q4 Earnings, Contrave Impresses - Analyst Blog Feb 26 2015
Takeda Regroups Singapore Operations in New, Expanded Office Feb 24 2015
Seattle Genetics (SGEN) Filed Supplemental BLA for Adcetris - Analyst Blog Feb 19 2015
Seattle Genetics Posts Narrower-than-Expected Loss in Q4 - Analyst Blog Feb 11 2015
Orexigen Gives Positive Updates on its Weight Loss Drug - Analyst Blog Feb 10 2015
AMAG's Q4 Loss Narrows Y/Y, Reiterates 2015 Outlook - Analyst Blog Feb 10 2015
AstraZeneca's Regulatory Filing for Lesinurad Accepted - Analyst Blog Jan 26 2015
Orexigen Therapeutics Gains On Diet Pill Nod From European Committee Dec 19 2014
Takeda Presents Phase 2 Data on Maintenance with Single-Agent Investigational Ixazomib in Patients... Dec 08 2014
Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin)... Dec 08 2014
Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS(R) (Brentuximab... Dec 08 2014
Seattle Genetics-Takeda's Adcetris Shows Long-Term Effect Dec 08 2014
Takeda's Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy... Dec 04 2014
Canon Inc. -- Moody's announces rating actions on Japanese corporates following sovereign downgrade Dec 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK